Current drug therapy for heart failure with reduced ejection fraction

Herz
D BerlinerJ Bauersachs

Abstract

The prevalence of heart failure has been steadily increasing during the past few years, with a further increase predicted in the years to come. Without treatment, the syndrome of heart failure has a very poor prognosis. Advances in drug treatments and the consequent implementation of a guideline-recommended drug therapy have significantly improved the prognosis in heart failure with reduced ejection fraction (HFrEF). Besides angiotensin-converting enzyme (ACE) inhibitors (ACEi) or angiotensin receptor blockers, beta-blockers and diuretics treatment with mineralocorticoid receptor antagonists and ivabradine have become standard in the therapy of symptomatic patients with HFrEF. Recently, the impact of the adequate dosage of ACEi and beta-blockers was emphasized again. Angiotensin receptor-neprilysin inhibition is an auspicious new therapeutic approach and is predicted to play a crucial role in heart failure treatment in the coming years. The role of cardiac glycosides in the modern era of heart failure therapy is the focus of a current randomized controlled trial. Last but not least, potassium binders such as the new substance patiromer might help in overcoming the problem of hyperkalemia, which frequently limits the dosing of v...Continue Reading

References

Aug 1, 1991·The New England Journal of Medicine·UNKNOWN SOLVD InvestigatorsJay N Cohn
Feb 20, 1997·The New England Journal of Medicine·UNKNOWN Digitalis Investigation Group
Oct 23, 2002·Circulation·Milton PackerUNKNOWN Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group
Apr 2, 2003·The New England Journal of Medicine·Bertram PittUNKNOWN Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators
Feb 2, 2006·The Canadian Journal of Cardiology·J Malcolm O ArnoldUNKNOWN Canadian Cardiovascular Society
Feb 3, 2006·International Journal of Clinical Practice·S Sulfi, A D Timmis
Mar 30, 2007·Clinical Science·Morag J YoungAmanda J Rickard
Aug 19, 2007·Heart·Arend Mosterd, Arno W Hoes
Jul 9, 2010·Journal of Cardiac Failure·UNKNOWN Heart Failure Society of AmericaMary N Walsh
Nov 16, 2010·The New England Journal of Medicine·Faiez ZannadUNKNOWN EMPHASIS-HF Study Group
Jan 22, 2011·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·A R Naylor, J-B Ricco
May 12, 2012·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Michael BöhmLuigi Tavazzi
Mar 13, 2013·JAMA : the Journal of the American Medical Association·Mihai GheorghiadeUNKNOWN ASTRONAUT Investigators and Coordinators
Mar 23, 2013·Methodist DeBakey Cardiovascular Journal·Biykem Bozkurt, Douglas L Mann
Jun 28, 2013·European Journal of Heart Failure·Luigi TavazziUNKNOWN SHIFT Investigators
Feb 5, 2014·Current Heart Failure Reports·Vittoria MastromarinoMassimo Volpe
Sep 2, 2014·The New England Journal of Medicine·John J V McMurrayUNKNOWN PARADIGM-HF Investigators and Committees
Nov 7, 2015·Journal of the American College of Cardiology·G William Dec
Apr 5, 2016·The New England Journal of Medicine·John J V McMurrayUNKNOWN ATMOSPHERE Committees Investigators
Jul 13, 2016·Circulation·Robert L PageUNKNOWN American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical
Nov 22, 2016·European Journal of Heart Failure·Jane A CannonUNKNOWN PARADIGM-HF Investigators and Committees
Mar 23, 2017·European Journal of Heart Failure·Emilia D'EliaMichele Senni
Apr 24, 2017·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Hanna FröhlichLutz Frankenstein
Sep 29, 2017·Korean Circulation Journal·Dominik Berliner, Johann Bauersachs
Oct 31, 2017·European Journal of Heart Failure·Stephen J Greene, Robert J Mentz
Jan 18, 2018·Herz·D Berliner, J Bauersachs

❮ Previous
Next ❯

Citations

May 21, 2019·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Dominik Berliner, Johann Bauersachs
Aug 12, 2021·Clinics·Raphael Dos Santos Coutinho E SilvaLuiz Felipe Pinho Moreira

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Cardiac Glycosides

Cardiac glycosides are a diverse family of naturally derived compounds that bind to and inhibit na+/k+-atpase. Discover the latest research on cardiac glycosides heres.

Related Papers

Current Heart Failure Reports
Alanna A MorrisDivya Gupta
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
Rex C Liu
Bulletin de l'Académie nationale de médecine
Michel Komajda
© 2022 Meta ULC. All rights reserved